Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)
Recruiting · NCT05940324 · Interventional (participants receive a specific treatment) · Lead sponsor: Stanford University
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The purpose of this study is to understand how ketamine works in the brain to bring about a reduction in OCD symptoms.
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Ages 18-65
- Meet the criteria for OCD diagnosis
- Failed at least 1 prior trial of standard first-line OCD treatment
- Agree to the following lifestyle modifications: comply with requirements for fasting prior to the Experimental Session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication study procedures.
- Able to provide informed consent
Exclusion criteria
- prior naltrexone or ketamine use/exposure
- Any current or past medical/psychiatric condition that makes participation unsafe in the opinion of the investigator or study physician
- Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control
- the presence of metal in the body that is contraindicated for MRI scans
- Eligibility Criteria for Healthy Volunteers:
- Inclusion Criteria:
- Ages 18-65
- Able to provide informed consent
- Exclusion Criteria:
- current or past use of psychotropic medication
- pregnant or nursing females
- the presence of metal in the body that is contraindicated for MRI scans
Where it is running
1 location listed across 1 US state.
- Department of Psychiatry & Behavioral Sciences - Stanford, California, United States